91 related articles for article (PubMed ID: 37121246)
1. Payer perceptions and use of value assessment tools in the United States.
Westrich K; Hydery T; Dharbhamalla V; Buelt L; Zheng C; Loo V; Graff J
J Manag Care Spec Pharm; 2023 May; 29(5):582-588. PubMed ID: 37121246
[No Abstract] [Full Text] [Related]
2. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
3. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
4. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
5. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
6. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
[TBL] [Abstract][Full Text] [Related]
7. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
[TBL] [Abstract][Full Text] [Related]
8. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
Schafer J; Galante D; Shafrin J
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
[TBL] [Abstract][Full Text] [Related]
9. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
[TBL] [Abstract][Full Text] [Related]
10. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
Westrich K; Buelt L; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
[TBL] [Abstract][Full Text] [Related]
11. The evolution of payer management of oncology drugs in the United States between 2017 and 2022.
Runyan A; Yi J; Honcz J
J Manag Care Spec Pharm; 2023 Oct; 29(10):1138-1149. PubMed ID: 37695273
[No Abstract] [Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Oncology Management in the United States.
Runyan A; Banks J; Bruni DS
J Manag Care Spec Pharm; 2019 Feb; 25(2):272-281. PubMed ID: 30698085
[TBL] [Abstract][Full Text] [Related]
14. A Survey of Payer Perspectives on Cannabis Use Disorder.
Kiselica AM; Duhig A; Montoya I; Skolnick P; Floyd J; Byars C
Subst Use Misuse; 2018 Nov; 53(13):2257-2264. PubMed ID: 29927691
[TBL] [Abstract][Full Text] [Related]
15. PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH.
Moloney R; Mohr P; Hawe E; Shah K; Garau M; Towse A
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):90-8. PubMed ID: 26168804
[TBL] [Abstract][Full Text] [Related]
16. Methodology for conducting a comprehensive product review in managed care.
Linnerooth S; Penley B; Sauvageau G; Ha J; Beal A; Craven J; Feeney E; Taddei-Allen P; Thomas N; Watkins J; Hydery T
J Manag Care Spec Pharm; 2023 Mar; 29(3):237-243. PubMed ID: 36840955
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.
Gerlach JA; Snow B; Prioli KM; Vertsman R; Patterson J; Pizzi LT
Am Health Drug Benefits; 2020 Sep; 13(4):136-142. PubMed ID: 33343812
[TBL] [Abstract][Full Text] [Related]
18. Health technology assessment and private payers' coverage of personalized medicine.
Trosman JR; Van Bebber SL; Phillips KA
J Oncol Pract; 2011 May; 7(3 Suppl):18s-24s. PubMed ID: 21886515
[TBL] [Abstract][Full Text] [Related]
19. Strengthening Multipayer Collaboration: Lessons From the Comprehensive Primary Care Initiative.
Anglin G; Tu HA; Liao K; Sessums L; Taylor EF
Milbank Q; 2017 Sep; 95(3):602-633. PubMed ID: 28895218
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]